• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@Medipol
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • Scopus İndeksli Yayınlar Koleksiyonu
  • View Item
  •   DSpace@Medipol
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • Scopus İndeksli Yayınlar Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma

Thumbnail

View/Open

Tam Metin / Full Text (218.0Kb)

Access

info:eu-repo/semantics/embargoedAccess

Date

2015

Author

Hazar, Volkan
Kesik, Vural
Aksoylar, Serap
Karakükçü, Musa
Öztürk, Gülyüz
Küpesiz, Alphan
Ataş, Erman
Öniz, Haldun
Kansoy, Savaş
Ünal, Ekrem
Tanyeli, Atila
Erbey, Fatih
Elli, Murat
Taçyıldız, Nurdan
Karasu, Gülsün Tezcan
Koçak, Ülker
Anak, Şema Sema
Yılmaz Bengoa, Şebnem
Sezgin, Gülay
Atay, Didem
Ünal, Emel
Uygun, Vedat
Kurucu, Nilgün
Kaya, Zühre
Yeşilipek, Akif

Metadata

Show full item record

Citation

Hazar, V., Kesik, V., Aksoylar, S., Karakükçü, M., Öztürk, G., Küpesiz, A. (2015). Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma. Pediatric Transplantation, 19(7), 745-752. https://dx.doi.org/10.1111/petr.12573

Abstract

This study evaluates the outcome of 66 pediatric patients with rrHL who underwent autoHSCT. Twenty-nine patients experienced early relapse, and 19 patients experienced late relapse. Of 18 newly diagnosed with HL, 13 were primary refractory disease and five had late responsive disease. At the time of transplantation, only 68% of the patients were chemosensitive. The majority of patients received BCNU+etoposide+ara-C+melphalan for conditioning (45/66), and peripheral blood (56/66) was used as a source of stem cells. After a median follow-up period of 39months, 46 patients were alive. At fiveyr, the probabilities of OS, EFS, the relapse rate, and the non-relapse mortality rate were 63.1%, 54.3%, 36.4%, and 9.1%, respectively. The probability of EFS in chemosensitive and chemoresistant patients at fiveyr was 72.3% and 19%, respectively (p<0.001). Multivariate analysis showed that chemoresistant disease at the time of transplantation was the only factor predicting limited both OS (hazard ratio=4.073) and EFS (hazard ratio=4.599). AutoHSCT plays an important role for the treatment of rrHL in children and adolescents, and survival rates are better for patients with chemosensitive disease at the time of transplantation.

WoS Q Kategorisi

Q4

xmlui.dri2xhtml.METS-1.0.item-scopusquality

Q2

Source

Pediatric Transplantation

Volume

19

Issue

7

URI

https://dx.doi.org/10.1111/petr.12573
https://hdl.handle.net/20.500.12511/3657

Collections

  • Makale Koleksiyonu [3444]
  • PubMed İndeksli Yayınlar Koleksiyonu [3752]
  • Scopus İndeksli Yayınlar Koleksiyonu [5794]
  • WoS İndeksli Yayınlar Koleksiyonu [5972]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Guide | Contact |

DSpace@Medipol

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide || Library || İstanbul Medipol University || OAI-PMH ||

Kütüphane ve Dokümantasyon Daire Başkanlığı, İstabul, Turkey
If you find any errors in content, please contact: [email protected]

Creative Commons License
DSpace@Medipol by İstanbul Medipol University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Medipol:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.